226 related articles for article (PubMed ID: 33491667)
1. Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis.
Aftabizadeh M; Li YJ; Zhao Q; Zhang C; Ambaye N; Song J; Nagao T; Lahtz C; Fakih M; Ann DK; Yu H; Herrmann A
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33491667
[TBL] [Abstract][Full Text] [Related]
2. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects.
Kujawski M; Zhang C; Herrmann A; Reckamp K; Scuto A; Jensen M; Deng J; Forman S; Figlin R; Yu H
Cancer Res; 2010 Dec; 70(23):9599-610. PubMed ID: 21118964
[TBL] [Abstract][Full Text] [Related]
3. CCR5 Blockade Suppresses Melanoma Development Through Inhibition of IL-6-Stat3 Pathway via Upregulation of SOCS3.
Tang Q; Jiang J; Liu J
Inflammation; 2015 Dec; 38(6):2049-56. PubMed ID: 26047948
[TBL] [Abstract][Full Text] [Related]
4. B cell-Derived IL35 Drives STAT3-Dependent CD8
Mirlekar B; Michaud D; Lee SJ; Kren NP; Harris C; Greene K; Goldman EC; Gupta GP; Fields RC; Hawkins WG; DeNardo DG; Rashid NU; Yeh JJ; McRee AJ; Vincent BG; Vignali DAA; Pylayeva-Gupta Y
Cancer Immunol Res; 2020 Mar; 8(3):292-308. PubMed ID: 32024640
[TBL] [Abstract][Full Text] [Related]
5. The anticancer peptide RT53 induces immunogenic cell death.
Pasquereau-Kotula E; Habault J; Kroemer G; Poyet JL
PLoS One; 2018; 13(8):e0201220. PubMed ID: 30080874
[TBL] [Abstract][Full Text] [Related]
6. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy.
Wu X; Cao Y; Xiao H; Li C; Lin J
Mol Cancer Ther; 2016 Nov; 15(11):2609-2619. PubMed ID: 27535971
[TBL] [Abstract][Full Text] [Related]
7. Impact of combination therapy with anti-PD-1 blockade and a STAT3 inhibitor on the tumor-infiltrating lymphocyte status.
Ashizawa T; Iizuka A; Maeda C; Tanaka E; Kondou R; Miyata H; Sugino T; Kawata T; Deguchi S; Mitsuya K; Hayashi N; Asai A; Ito M; Yamaguchi K; Akiyama Y
Immunol Lett; 2019 Dec; 216():43-50. PubMed ID: 31586551
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor activity of the STAT3 inhibitor STX-0119 occurs via promotion of tumor-infiltrating lymphocyte accumulation in temozolomide-resistant glioblastoma cell line.
Akiyama Y; Nonomura C; Ashizawa T; Iizuka A; Kondou R; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Asai A; Ito M; Kiyohara Y; Yamaguchi K
Immunol Lett; 2017 Oct; 190():20-25. PubMed ID: 28716484
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effects of CpG oligodeoxynucleotide and STAT3 inhibitory agent JSI-124 in a mouse melanoma tumor model.
Molavi O; Ma Z; Hamdy S; Lai R; Lavasanifar A; Samuel J
Immunol Cell Biol; 2008; 86(6):506-14. PubMed ID: 18392040
[TBL] [Abstract][Full Text] [Related]
10. CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells.
Herrmann A; Priceman SJ; Swiderski P; Kujawski M; Xin H; Cherryholmes GA; Zhang W; Zhang C; Lahtz C; Kowolik C; Forman SJ; Kortylewski M; Yu H
J Clin Invest; 2014 Jul; 124(7):2977-87. PubMed ID: 24892807
[TBL] [Abstract][Full Text] [Related]
11. Applying Small Molecule Signal Transducer and Activator of Transcription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer Therapeutics.
Arpin CC; Mac S; Jiang Y; Cheng H; Grimard M; Page BD; Kamocka MM; Haftchenary S; Su H; Ball DP; Rosa DA; Lai PS; Gómez-Biagi RF; Ali AM; Rana R; Hanenberg H; Kerman K; McElyea KC; Sandusky GE; Gunning PT; Fishel ML
Mol Cancer Ther; 2016 May; 15(5):794-805. PubMed ID: 26873728
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation.
Ashizawa T; Miyata H; Ishii H; Oshita C; Matsuno K; Masuda Y; Furuya T; Okawara T; Otsuka M; Ogo N; Asai A; Akiyama Y
Int J Oncol; 2011 May; 38(5):1245-52. PubMed ID: 21369699
[TBL] [Abstract][Full Text] [Related]
13. A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling.
Kim D; Lee IH; Kim S; Choi M; Kim H; Ahn S; Saw PE; Jeon H; Lee Y; Jon S
Cancer Res; 2014 Apr; 74(8):2144-51. PubMed ID: 24576829
[TBL] [Abstract][Full Text] [Related]
14. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells.
Herrmann A; Kortylewski M; Kujawski M; Zhang C; Reckamp K; Armstrong B; Wang L; Kowolik C; Deng J; Figlin R; Yu H
Cancer Res; 2010 Oct; 70(19):7455-64. PubMed ID: 20841481
[TBL] [Abstract][Full Text] [Related]
15. Th17 cells inhibit CD8
Wang D; Yu W; Lian J; Wu Q; Liu S; Yang L; Li F; Huang L; Chen X; Zhang Z; Li A; Liu J; Sun Z; Wang J; Yuan W; Zhang Y
J Hematol Oncol; 2020 Jun; 13(1):68. PubMed ID: 32503584
[TBL] [Abstract][Full Text] [Related]
16. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.
Blaskovich MA; Sun J; Cantor A; Turkson J; Jove R; Sebti SM
Cancer Res; 2003 Mar; 63(6):1270-9. PubMed ID: 12649187
[TBL] [Abstract][Full Text] [Related]
17. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
[TBL] [Abstract][Full Text] [Related]
18. Valtrate as a novel therapeutic agent exhibits potent anti-pancreatic cancer activity by inhibiting Stat3 signaling.
Chen L; Feng D; Qian Y; Cheng X; Song H; Qian Y; Zhang X; Wu Y; Lv H; Liu Q; Cheng G; Yang B; Gu M
Phytomedicine; 2021 May; 85():153537. PubMed ID: 33744595
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of tripterine via cell-penetrating peptide-coated nanostructured lipid carriers in a prostate cancer model.
Yuan L; Liu C; Chen Y; Zhang Z; Zhou L; Qu D
Int J Nanomedicine; 2013; 8():4339-50. PubMed ID: 24235831
[TBL] [Abstract][Full Text] [Related]
20. Targeting colon cancer with the novel STAT3 inhibitor bruceantinol.
Wei N; Li J; Fang C; Chang J; Xirou V; Syrigos NK; Marks BJ; Chu E; Schmitz JC
Oncogene; 2019 Mar; 38(10):1676-1687. PubMed ID: 30348989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
